U-shaped Association Between Mean Platelet Volume And Short-term

1

Survival In Chinese Patients With Heart Failure 2 3 Yuan-lei Huanga, Qi Zhoua, Tao Zhenga* The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, 4 5 China Yuan-lei Huang 6 7 Department: Department of Cardiovascular Medicine 8 Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine 9 Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province 10 Qi Zhou 11 Department: Department of Cardiovascular Medicine 12 Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine 13 Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province 14 Corresponding Author: 15 Tao Zheng 16 Department: Department of Cardiovascular Medicine 17 Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine 18 Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province 19 Tel:8615985184796 20 E-mail: oulaosisonzhengtao@163.com 21 22 23 24 25

26 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

Keywords: Mean platelet volume, Association, Nonlinearity, Non-obese, 6 months all-cause mortality

Background: Mean Platelet Volume (MPV) has been proposed as a potential predictor of increased mortality risk at 6 months among Chinese patients with heart failure (HF). However, the current evidence supporting this association is limited.

Methods: This study aimed to investigate the relationship between MPV and HF short-term survival status. The data was obtained from a publicly accessible HF database in Zigong, Sichuan, and included information on 2008 Chinese patients. Baseline MPV was considered as the exposure while HF short-term survival status was the outcome. Two models, a binary logistic regression model and a two-piecewise linear model, were used to analyze the data.

Results: The study revealed a U-shaped relationship between MPV and all-cause mortality in HF patients. When MPV levels were less than 9.8, every unit increase in MPV was associated with a 91% reduction (RR: 0.09; 95% CI: 0.03-0.24; P=0.0001) in the risk of death over the next six months. In contrast, at MPV levels above 9.8, each unit increase in MPV was linked to a 27% increase (RR: 1.27; 95% CI: 1.01-1.61; P=0.0434) in the probability of dying within the same period. Stratification by obesity status revealed no significant association between MPV and death in the obese population, while the same U-shaped association was observed among non-obese participants.

Conclusion: The present study provides evidence of a U-shaped association between MPV and short-term survival in Chinese patients with heart failure. These findings suggest that MPV may serve as a potential prognostic marker for HF. However, further studies are needed to validate these results and to explore the underlying mechanisms of this association. The observed U-shaped association did not apply to obese patients, suggesting that the effect of MPV on mortality risk in HF patients may be influenced by body weight.

Introduction

 The mean platelet volume (MPV) is a low-cost and easy-to-use blood count indicator that has been suggested to play a critical role in platelet reactivity, inflammation, thrombosis, and heart failure (HF) in previous studies(1-4). MPV is frequently used as a surrogate measure of platelet function since it reflects both platelet size and activity, with larger platelets being associated with increased platelet aggregation, thromboxane production, platelet globulin release, and adhesion molecule expression(5), Elevated MPV levels have been found in various disease states, particularly in individuals with cardiovascular risk factors such as smoking, diabetes, obesity, hypertension, and hyperlipidemia (6-10), indicating a need for careful cardiovascular risk assessment (11). Excessively high MPV levels are also associated with increased cardiovascular disease risk and a poor prognosis.

HF is a worldwide pandemic disease that affects at least 26 million people worldwide and is increasing in prevalence as the population ages(12). In China, the number of people suffering from HF has risen to 1.3 percent of the entire population(13). HF not only affects patients' quality of life, but it also has a substantial financial impact on their families and society. According to figures, HF accounts for 17 percent of total health expenditures for cardiovascular illness in the United States(14), and total expenses are expected to rise by 127 percent between 2012 and 2030(15). Given the high mortality rate as well as the high financial burden caused by HF, researchers have called HF "the last war of cardiovascular disease in the 21st century."(16, 17)

In recent years, MPV has piqued interest as a novel prognostic marker in patients with cardiovascular illness. However, evidence linking MPV to all-cause mortality in HF is lacking. Budak et al. discovered a positive correlation between BNP and MPV(18). Furthermore, Kaya (19) and Kandis(2) reported that MPV upon admission was highly linked to in-hospital mortality or death at 6 months, even after controlling for typical HF-related risk variables. However, the majority of the information presented above has come from Western countries. Besides, evidence on the link between MPV and short-term mortality in patients with HF in the Chinese population is limited. Given China's vast population and rising HF prevalence, a better understanding of the relationship between MPV and short-term mortality risk in HF will be beneficial for future predictive model-driven investigations. In light of this, this study offers a secondary data analysis of a large sample HF database to investigate the relationship between MPV and HF short-term prognosis. This study will also reveal these results.

Participants and methods

Data source and study design

This study is a retrospective cohort analysis based on publicly available and published data obtained from clinical records of hospitalized inpatients with confirmed heart failure (HF) at the Fourth People's Hospital in Zigong City, Sichuan Province, China, between December 2016 and June 2019. The data was downloaded from the PhysioNet website (10.13026/8a9e-w734), and a detailed description of the dataset is available in the literature(20). The dataset has been deidentified to protect patient privacy. All data were extracted from the hospital's electronic medical record system, and the Ethics Committee of the Fourth People's Hospital of Zigong approved the study (approval number: 2020-010). Patient informed consent was not required due to the retrospective nature of the study and the anonymization of patient information. The outcome variable was 6-month all-cause mortality in HF patients, recorded as a dichotomous variable in the original data, and the target independent variable was baseline MPV, recorded as a continuous variable.

Study population

A sample of 2,008 individuals with HF was initially included in the dataset; however, after applying a set of screening criteria, 103 cases were excluded due to missing MPV data, leaving 1,905 cases for data analysis (for details, refer to Figure 1). The diagnosis of HF was made based on the criteria established by the European Society of Cardiology (ESC), and ICD codes were used to collect data on heart failure. The data provider has furnished specific details on the dataset.

Variables

Mean platelet volume

The mean platelet volume (MPV) was initially recorded as a continuous variable in the raw data. However, to investigate the stability of the results and ensure the robustness of the findings, we further transformed the MPV into a categorical variable based on quartiles. Specifically, the data was divided into four subgroups: Q1 (MPV range: 7.70-10.80, n=475), Q2 (MPV range: 10.90-12.00, n=475), Q3 (MPV range: 12.10-13.20, n=476), and Q4 (MPV range: 13.30-17.60, n=479). This approach allowed us to examine whether the effect values varied equidistantly and to compare the consistency of the results obtained using MPV as a continuous versus a categorical variable.

6-month all-cause death in HF patients

The primary outcome measure of this study was six-month all-cause mortality in HF patients. The original dataset provided information on the survival of HF patients at 6 months, represented by a binary variable where 0 indicates survival and 1 indicates death.

Covariates

115116

117

118

119

120

121122

123124

125

126127

128

129

130131

132

133134

135

136137

138

139140

141

142

143

144

145146

147

148

149

150

151

152153

154155

156

157

158

In this analysis, potential confounding variables were selected based on prior literature (21-23) that investigated risk factors associated with adverse outcomes in HF, as well as our clinical experience. The following variables were included: age and gender as demographic factors, Charlson Comorbidity Index (CCI) as a measure of co-morbidities, statins, vasodilators, Ras blockers, and positive inotropes as pharmaceutical factors, high-sensitivity troponin, glomerular filtration rate, and BNP as biomarkers, and BMI, NYHY classification, and number of hospitalizations as illness features and anthropometric factors.

Statistical analysis

Continuous variables were expressed as mean \pm standard deviation (SD) (Gaussian distribution) or median (range) (skewed distribution), and categorical variables were expressed as numbers and percentages. The γ 2 (categorical variables), one-way ANOVA test (normal distribution), or Kruskal-Whallis H test (skewed distribution) were used to detect differences in the distribution of baseline information across MPV subgroups (quartiles). We examined univariate and multivariate binary logistic regression models to determine the association between the two. To observe the stability of changes in effect values under multiple strategy alterations, we simultaneously display three models. The unadjusted model, or Model 1, does not account for covariates. The model with the fewest adjustments simply for sociodemographic components is Model 2. Model 3 was the one that was completely factor-adjusted. because the binary logistic regression model was unable to account for the nonlinear relationships. We utilized a generalized additive model (GAM) and a smoothed curve fit to examine whether MPV was nonlinearly related to the probability of short-term death in HF (penalized spline method). If nonlinearity was detected, we first used the recursive algorithm + bootstrapping to calculate the inflection point extremely credible intervals, and then constructed two-piece binary logistic regression models on both sides of the inflection point.

To illustrate the robustness of our results, we performed a sensitivity analysis. We transformed mean platelet volume into a categorical variable based on quartiles and calculated p for trend. The aim was to see whether the association with outcome was consistent when MPV was used as a continuous variable versus when it was used as a categorical variable.

R (http://www.r-project.org, R Foundation) and EmpowerStats (http://www.empowerstats.com, X & Y Solutions, Inc., Boston, MA) are statistical applications that were utilized to model the data. Statistical significance was defined as p-values of 0.05 (two-sided).

Results

Baseline characteristics of participants

Table 1 summarizes the baseline characteristics of all HF patients, categorized into quartiles based on their MPV levels. Nearly 70% of the patients were below the age of 70. Significant differences were observed between the various MPV level groups (Q1-Q4) for eGFR, Ln BNP, age, sex, use of Ras-Blockers, Inotropes, and diuretics (P < 0.05). Compared to the Q4 group, the Q1, Q2, and Q3 groups had lower eGFR, Ln hs-Tnl, and LnBNP levels, and a smaller percentage

of females, a greater percentage of individuals over 70, and a lower percentage of RAS blockers, vasodilators, and diuretics. However, there was no statistically significant difference between the Q1-Q4 groups in terms of BMI, Charlson comorbidity score, NYHA classification, Vasodilator use, Statin use, number of hospitalizations, or 6-month all-cause mortality (P > 0.05).

Results of a binary logistic regression model's multivariate analysis

We employed a binary logistic regression model to examine the association between MPV and the 6-month risk of death in HF patients. Our analysis did not reveal a significant relationship between MPV and all-cause mortality (RR, 0.90; 95% CI: 0.77 to 1.06; P=0.1920). Furthermore, the minimally-adjusted (RR, 0.90, 95% CI: 0.77 to 1.06; P=0.2054) and fully-adjusted (RR, 0.94, 95% CI: 0.78 to 1.13; P=0.4888) models yielded identical results despite different adjustment procedures.

To verify the consistency of our findings, we categorized MPV into quartiles and calculated P for trend to compare with the results obtained from MPV as a continuous variable. As shown in Table 2, Our analysis revealed that RR had unequal variation across MPV subgroups (Q1-Q4), and P for trend values were discordant with those obtained using MPV as a continuous variable. These findings suggest that a non-linear relationship between MPV and all-cause mortality cannot be excluded.

Using generalized summation models to solve nonlinear issues

We found that the association between MPV and short-term all-cause mortality in HF patients was non-linear using a generalized summation model and smoothed curve fitting (Figure 2). A two-piecewise linear model was developed on both sides of the inflection point, which was obtained using a recursive approach (Table 3). The non-linear results showed a U-shaped relationship between MPV and 6-month mortality. Positive results were observed when MPV was greater than 9.8 (RR, 1.27; 95% CI, 1.01 to 1.61), indicating that each 1fL increase in MPV was associated with a 27% increase in the risk of death. Negative results were found when MPV was less than 9.8 (RR, 0.09; 95% CI, 0.03 to 0.24), indicating that each 1fL increase in MPV was associated with a 91% reduction in the risk of death. Additionally, we stratified the individuals into different obesity categories and found no association between MPV and mortality in the obese group. In contrast, in the non-obese population, the same U-shaped relationship between MPV and 6-month mortality was observed. At MPV < 9.7, the association between MPV and 6-month mortality was negative (RR, 0.08; 95% CI, 0.03 to 0.22), indicating that each 1fL increase in MPV was associated with a 92% reduction in mortality risk; at MPV > 9.7 1fL, the association between MPV and 6-month mortality was positive (RR, 1.29; 95% CI, 1.02 to 1.64), indicating that each 1fL increase in MPV was associated with a 29% increase in the risk of death.

Discussion

159

160

161

162163

164

165

166

167

168169

170

171

172173

174175

176

177

178179

180181

182

183 184

185

186187

188

189

190 191

192

193 194

195

196 197

198

199

200

201202

Our results imply that there is a U-shaped link between mean platelet volume and short-term mortality in HF in this cohort study. Both low and high MPV levels were linked to higher all-cause mortality in HF. However, this association did not hold true for obese individuals with HF. This discovery offers a priori support for upcoming model-driven studies and may have ramifications for how MPV levels are interpreted in clinical settings. As one of the most prevalent clinical markers, understanding the true relationship between MPV and a poor prognosis in HF will aid in the development of more accurate models. Our findings will also assist clinicians in making a more precise early evaluation of a patient's future risk linked with MPV, even though

this initial assessment is just approximate. Additionally, compared to other markers (blood glucose, potassium, etc.), which might alter as a result of various situations, MPV is a more stable measure.

203204

205

206207

208

209

210

211212

213

214

215

216217

218

219

220

221222

223

224225

226

227228

229

230

231

232

233234

235

236

237238

239

240

241

242

243244

245246

Dilated chambers, poor contractility, local ventricular wall abnormalities, and combined atrial fibrillation may promote thromboembolism by facilitating intracardiac blood flow arrest, which is one of the possible mechanisms of poor prognosis in HF given that MPV is known to be a strong indicator of platelet activation and congestive HF is characterized by an increase in thromboembolic events(24). According to Jafri(25) et al., the coagulation system and platelet activation (increased plasma platelet factor 4, b-thromboglobulin) have been demonstrated to be more susceptible in patients with severe HF and poor ejection fraction, The relationship between platelet activation and a bad prognosis for HF stems from the possibility that these conditions may contribute to the development of the disease by producing ischemic episodes, impairing left ventricular function, and promoting intracardiac thrombosis. Chronic HF itself may increase the risk of platelet abnormalities and thrombosis through increased catecholamine release, haemodynamic changes, vascular factors, nitric oxide, cytokines, and comorbid conditions (26-28). The increased cytokine and catecholamine release observed in patients with severe HF is associated with platelet activation and higher levels of MPV. Therefore, by reducing excessive catecholaminergic activity, some studies have reduced MPV levels in patients with HF, thereby reducing mortality and hospitalization in HF(29, 30). In contrast, we discovered in our study that a low MPV was likewise linked to a higher chance of passing away. The occurrence is currently being reported for the first time, although no mechanisms have been found to explain it. Additionally, we discovered various MPV and mortality trends across states with obesity. We hypothesize that the absence of a correlation between the two in the obese group may be due to a lesser correlation between MPV and mortality in this cohort and a larger correlation between BMI and the risk of death. Of course, more data is required to support our findings given the tiny obese population in our study.

While there are some similarities and some discrepancies between our results and those of earlier studies(31, 32), they all point to the possibility of a higher MPV in HF. A previous study(19) first demonstrated that MPV levels above 9.1 fL were an independent predictor of shortto mid-term HF-related hospitalization in outpatients with stable HFrEF in SR. However, that study had a small sample size and was restricted to HF patients with reduced ejection fraction, whereas the current study was not. Kandis et al(2), conducted research. The best cutoff for indicating elevated risk was > 10.5 fl. However, the cohort of patients in that study showed higher levels of urea, serum creatinine, and systolic blood pressure in patients who passed away during follow-up, suggesting a stronger impact of the patient's initial systolic blood pressure, BUN levels, and creatinine. In a cohort study(33) of the condition, an MPV value of > 9 fL was discovered to be a potential predictor of rehospitalization and 1-year mortality in patients with decompensated chronic HF in a cohort study. However, the study's participants were those with decompensated chronic HF who were hospitalized (NYHA class IV HF or acute pulmonary oedema). The study has a limited sample size (n = 130) and no sensitivity analysis. By comparing the association between the HF marker BNP and MPV, Budak et al. Error! Reference source not found. discovered that MPV levels and brain natriuretic peptide (BNP) values were positively associated in patients referred to the emergency room with acute HF. According to the scientists, MPV can be a sign of the severity and clinical condition of acute HF disease. Taking into account study design,

demographics, and other characteristics, we think the following factors are responsible for the results' variations.

Our clinical relevance can be seen in the following ways: The previous finding that high MPV is strongly associated with a high risk of death in HF patients also holds true for the Chinese population, according to our findings. In addition, we discovered that lower MPV is also strongly associated with a high risk of death in HF patients, a finding that has never been previously reported. This study suggests that in the future, doctors utilizing MPV as an assessment indicator may need to include a patient's obesity status when making clinical judgments or first prognosis assessments of patients. This offers fresh proof of MPV's clinical value.

Study advantages and limitations

We present a study with significant benefits, outlined below. Firstly, the use of large sample sizes enhances our statistical power. Secondly, the covariate information in our data is highly complete with few gaps. Thirdly, our work delves into non-linearity, providing further justification and insight. In comparison to previous studies, this allows for a greater understanding of the relationship between MPV and all-cause mortality. Lastly, we applied rigorous statistical corrections to address potential confounding variables, given the observational nature of our study.

However, some limitations should be acknowledged. Firstly, we only utilized baseline MPV measurements upon admission and were therefore unable to track MPV trends throughout hospitalization and their impact on outcomes. Secondly, the study was geographically and racially restricted to the Chinese population. Lastly, despite accounting for known potential confounders, residual confounders may still exist in any observational study.

Conclusion

Our study investigated the association between baseline mean platelet volume and 6-month all-cause mortality in patients with heart failure. We found a U-shaped association, where the all-cause death rate increased at both low and high mean platelet volumes. However, we did not observe this connection in the population with obesity-related heart failure. These results have important clinical and public health implications, but additional prospective trials are needed to validate our findings and clarify their clinical implications.

Data Availability Statement

Publicly available datasets were analyzed in this study. This data can be found here: https://doi.org/10.13026/8a9e-w734.

Ethics Statement

Studies involving human subjects were reviewed and approved by the Ethics Committee of the Fourth People's Hospital of Zigong. In accordance with national legislation and institutional requirements, written informed consent for participation in this study was not required.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Funding

Funding

292

293

294295

296

297298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

This study was funded by the Science and Technology Support Plan of Guizhou Provincial Department of Science and Technology in 2020 (Project No. Qianke Support [2021] General 064). Acknowledgments We thank Chen Chi for their guidance and review of this manuscript. Authors' Contributions Y-LH collected documents and wrote the manuscript. QZ also contributed equally to this work. Y-LH and QZ are co-first authors. TZ reviewed and performed critical revision of the manuscript. All authors have read and agreed to the published version of the manuscript. References: Stokes KY, Granger DN. Platelets: a critical link between inflammation and microvascular dysfunction. J Physiol. 2012;590(5):1023-34. 2. Kandis H, Ozhan H, Ordu S, Erden I, Caglar O, Basar C, et al. The prognostic value of mean platelet volume in decompensated heart failure. Emerg Med J. 2011;28(7):575-8. 3. Kamath S, Blann AD, Lip GY. Platelets and atrial fibrillation. Eur Heart J. 2001;22(24):2233-42. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(1):148-56. 5. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost. 2003;9(3):177-90. 6. Pathansali R, Smith N, Bath P. Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets. 2001;12(5):292-7. 7. Nadar S, Blann AD, Lip GY. Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med.

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

2004;36(7):552-7. Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in 8. elderly patients with risk factors for atherosclerosis. Clin Lab Haematol. 1992;14(4):281-7. Inoue H, Saito M, Kouchi K, Asahara SI, Nakamura F, Kido Y. Association between mean platelet volume in the pathogenesis of type 2 diabetes mellitus and diabetic macrovascular complications in Japanese patients. J Diabetes Investig. 2020;11(4):938-45. 10. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract. 2005;59(8):981-2. 11. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509-15. 12. Lund LH, Savarese G. Global Public Health Burden of Heart Failure. Cardiac Failure Review. 2017;03(01). 13. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 2013;77(9):2209-17. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4-25. 15. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360. 16. Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost-effectiveness of heart failure therapies. Nat Rev Cardiol. 2013;10(6):338-54. 17. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, et al. Survival of

patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83(5):505-10.

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

Budak YU, Huysal K, Demirci H. Correlation between mean platelet volume and B-type natriuretic peptide concentration in emergency patients with heart failure. Biochem Med (Zagreb). 2015;25(1):97-102. 19. Kaya H, Kutay Yildirimli M, Kurt R, Beton O, Birhan Yilmaz M. Mean Platelet Volume as a Predictor of Heart Failure-Related Hospitalizations in Stable Heart Failure Outpatients with Sinus Rhythm. Acta Cardiol Sin. 2017;33(3):292-300. 20. Zhang Z, Cao L, Chen R, Zhao Y, Lv L, Xu Z, et al. Electronic healthcare records and external outcome data for hospitalized patients with heart failure. Sci Data. 2021;8(1):46. 21. Wang R, Cao Z, Li Y, Yu K. Mean platelet volume provides an additive value in differentiating congestive heart failure from chronic obstructive pulmonary disease. Int J Cardiol. 2015;179:201-2. 22. Dahlen B, Schulz A, Gobel S, Trobs SO, Schwuchow-Thonke S, Spronk HM, et al. The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study. ESC Heart Fail. 2021;8(4):2991-3001. 23. Cheng YL, Sung SH, Cheng HM, Hsu PF, Guo CY, Yu WC, et al. Prognostic Nutritional Index and the Risk of Mortality in Patients With Acute Heart Failure. J Am Heart Assoc. 2017;6(6). 24. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333(18):1190-5. 25. Moore EE, Moore HB, Kornblith LZ, Neal MD, Hoffman M, Mutch NJ, et al. Trauma-induced coagulopathy. Nat Rev Dis Primers. 2021;7(1):30. 26. Stach K, Kalsch AI, Nguyen XD, Elmas E, Kralev S, Lang S, et al. 1alpha,25-dihydroxyvitamin D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

cells. Cardiology. 2011;118(2):107-15. 27. Karabacak M, Dogan A, Aksoy F, Ozaydin M, Erdogan D, Karabacak P. Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure. Angiology. 2014;65(6):533-7. 28. Handtke S, Steil L, Greinacher A, Thiele T. Toward the Relevance of Platelet Subpopulations for Transfusion Medicine. Front Med (Lausanne). 2018;5:17. 29. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8. 30. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-25. 31. Martinez-Quintana E, Rodriguez-Hernandez JL, Riano-Ruiz M, Rodriguez-Gonzalez F. Mean platelet volume and major adverse cardiovascular events in congenital heart disease patients. Clin Hemorheol Microcirc. 2019;72(4):327-37. 32. Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H, et al. Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study. Thromb Res. 2011;128(4):358-60. 33. Andrei CL, Catana A, Sinescu CJ, Mirica A, Ceban O, Chioncel VP, et al. Mean Platelet Volume: A Possible Predictor for Patients with Decompensated Chronic Heart Failure. Int J Gen Med. 2022;15:4131-40.





Figure 1





medRxiv preprint doi: https://doi.org/10.1101/2023.06.16.23291510; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



Table 1: Baseline characteristics of patients with HF grouped by mean platelet volume(quartile)

	01/7 70 10 80)	Q2 (10.90-	Q3(12.10-	Q4 (13.30-	P-value
	Q1(7.70-10.80)	12.00)	13.20)	17.60)	r-vaiu
N	475	475	476	479	
BMI mean±SD kg/m² nt doi: https://doi.org/10.1101/2023.06.16.232915 not certified by peer review) is the author/funde It is made available unde	21.37 ± 9.58 510; this version posted June 20, er, who has granted medRxiv a lice	21.40 ± 3.99 2023. The copyright holder tense to display the preprint	23.22 ± 25.08 for this preprint in perpetuity.	21.37 ± 6.72	0.103
It is made available unde	er a CC-BY 4.0 International licen	se.			
<28	452 (95.16%)	443 (93.26%)	442 (92.86%)	450 (93.95%)	
>=28	23 (4.84%)	32 (6.74%)	34 (7.14%)	29 (6.05%)	
Ln hs-Tnl , mean±SD	-2.86 ± 1.38	-2.78 ± 1.44	-2.73 ± 1.50	$\textbf{-2.98} \pm 1.38$	0.043
eGFR, mean±SD,	66 55 ± 38 66	66.27 ± 37.03	66 02 ± 34 53	73 62 ± 36 11	0.005
mL/min/1.73 m ²	00.55 ± 56.00	00.27 ± 37.03	00.92 ± 34.33	75.02 ± 50.11	0.003
Ln BNP, mean±SD	6.33 ± 1.25	6.61 ± 1.25	6.59 ± 1.23	6.63 ± 1.19	<0.00
Charles comorbidity	1.93 ± 0.92	1.86 ± 0.98	1.83 ± 0.96	1.83 ± 0.99	0.381
score,mean±SD	1.75 ± 0.72	1.00 ± 0.70	1.05 ± 0.70	1.00 ± 0.55	0.501
Sex, n (%)					0.034
Male	188 (39.58%)	207 (43.58%)	222 (46.64%)	183 (38.20%)	
Female	287 (60.42%)	268 (56.42%)	254 (53.36%)	296 (61.80%)	
Age, n (%)					0.003
≤70 years old	102 (21.47%)	120 (25.26%)	132 (27.73%)	152 (31.73%)	
>70 years old	373 (78.53%)	355 (74.74%)	344 (72.27%)	327 (68.27%)	

	NYHA classification, n					0.655
	(%)					0.655
	II	80 (16.84%)	86 (18.11%)	82 (17.23%)	84 (17.54%)	
	III	247 (52.00%)	237 (49.89%)	243 (51.05%)	265 (55.32%)	
	IV	148 (31.16%)	152 (32.00%)	151 (31.72%)	130 (27.14%)	
medRxiv preprint (which was no	doi: https://doi.org/10.1101/2023.06.16.23291510; ot certified by peer review) is the author/funder, w It is made available under a	this version posted June 20, 2 tho has granted medRxiv a lice	2023. The copyright holder f	or this preprint in perpetuity.		0.616
	No No		164 (34.53%)		156 (32.57%)	
	Yes	315 (66.32%)	311 (65.47%)	330 (69.33%)	323 (67.43%)	
	Ras-Blocker use, n (%)					<0.001
	No	56 (11.79%)	25 (5.26%)	34 (7.14%)	25 (5.22%)	
	Yes	419 (88.21%)	450 (94.74%)	442 (92.86%)	454 (94.78%)	
	Inotropes use, n (%)					< 0.001
	No	159 (33.47%)	134 (28.21%)	111 (23.32%)	106 (22.13%)	
	Yes	316 (66.53%)	341 (71.79%)	365 (76.68%)	373 (77.87%)	
	Diuretic use, n (%)					0.002
	No	16 (3.37%)	2 (0.42%)	10 (2.10%)	4 (0.84%)	
	Yes	459 (96.63%)	473 (99.58%)	466 (97.90%)	475 (99.16%)	
	Statin use, n (%)					0.514
	No	271 (57.29%)	277 (58.44%)	293 (61.81%)	279 (58.25%)	
	Yes	202 (42.71%)	197 (41.56%)	181 (38.19%)	200 (41.75%)	
	Number of					0.254

hospitalizations, n (%)

≤1 429 (90.32%) 440 (92.63%) 444 (93.28%) 447 (93.32%)

>1 46 (9.68%) 35 (7.37%) 32 (6.72%) 32 (6.68%)

6 months all-cause

0.374

mortality, n (%)

medRxiv preprint doi: https://doi.org/10.1101/2023.06.16.23291510; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.

Death

18 (3.79%)

15 (3.16%)

9 (1.89%)

14 (2.92%)

Note: The difference between the sample sum of each column and the total number shown in

Table 1 is due to missing data

Abbreviation:

BMI: body mass index

Hs-Tnl: High-sensitivity troponin I

BNP: B-type natriuretic peptide

NYHA: New York Heart Association

eGFR: estimated glomerular filtration rate

Table 2: The association between MPV and all-cause mortality using binary logistic regression model

_							
		Non-adjusted model RR, 95%CI, P value	Minimally-adjusted model RR, 95%CI, P value	Fully-adjusted model RR, 95%CI, P value			
edRxiv preprin	6 months all-cause mortality at doi: https://doi.org/10.1101/2023.06.16.23291510; this	s version posted June 20, 2023. The copyright by	older for this preprint				
(which was n	oot certified by peer review) is the author/funder, who It is made available under a CC	has granted medRxiv a license to display the pre	0.90 (0.77, 1.06)	0.94 (0.78, 1.13)			
	MPV (continuous variable)	0.90 (0.77, 1.06) 0.1920		0.94 (0.78, 1.15)			
			0.2054	0.4888			
	MPV (grouped by quartile)						
	Q 1	Ref	Ref	Ref			
	Q2	0.02 (0.41, 1.60, 0.5055	0.82 (0.41, 1.65) 0.69 (0.32, 1.5				
		0.83 (0.41, 1.66) 0.5955	0.5753	0.3554			
	02	0.40.(0.22.1.10).0.0920	0.48 (0.21, 1.08)	0.49 (0.20, 1.18)			
	Q3	0.49 (0.22, 1.10) 0.0839	0.0758	0.1098			
	Q4	0.76 (0.29, 1.56) 0.4595	0.78 (0.38, 1.59)	0.94 (0.42, 2.07)			
		0.76 (0.38, 1.56) 0.4585	0.4883	0.8734			
	P for trend	0.2663	0.2787	0.6522			

Abbreviation:

RR: Relative risk

CI: Confidence interval

Non-adjusted model: No covariates were adjusted for

Minimally-adjusted model: We only adjusted for age and sex




Table 3: Exploring the non-linear relationship between MPV and all-cause mortality

	BMI (kg/m^2) grouping	<28	>=28	Total			
	Fitting model by standard binary	1.03 (0.83, 1.27)	1.00 (0.00, Inf)	1.01 (0.81, 1.25)			
	logistic regression model	0.8177	1.0000	0.9558			
	Fitting model by two-piecewise linear						
	model						
medRxiv preprint doi: https://doi.org (which was not certified by ped	Inflection point(95%CI) https://doi.org/10.1101/2023.06.16.23291510; this version posted J ertified by peer review) is the author/funder, who has granted median entire the impact of the control of th	9.7 une 20, 2023. The copyright holde xxiv a license to display the preprir	9.4 Ir for this preprint to the propertion of the prepertion of the prepertion of the propertion of the prepertion of th	9.8			
	It is made available under a CC-BY 4.0 Internation	0.08 (0.03, 0.22)	1.00 (0.00, Inf)	0.09 (0.03, 0.24)			
	Time Point	<0.0001	1.0000	<0.0001			
	> inflection point	1.29 (1.02, 1.64)	1.00 (0.00, Inf)	1.27 (1.01, 1.61)			
		0.0334	1.0000	0.0434			
	P for log likelihood ratio test	<0.001	1.000	<0.001			

We adjusted for all covariates presented in table 1.